OFFICE-CJT
Seven international musicians held a live-streaming concert on September 30, 2020, at Absolute Blue in Ikebukuro, Tokyo, featuring progressive jazz music mixed with traditional Japanese sounds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005264/en/
YOUTUBE: https://www.youtube.com/watch?v=BjAHU1IfLh8
The concert was hosted by Creative Jazz Trio with four guest performers. Since 2014, the trio has been actively performing a unique blend of classic and jazz music.
The guest performers included University of Science and Arts of Chiapas (UNICACH) Junior Professor Keiko Kotoku, the youngest soloist winner of second prize in the Universal Marimba Competition 2013 in Belgium. She also won first prize in Duo category in the same competition.
Among other international guest musicians were traditional Japanese Gagaku artists Motonori Miura (hichiriki) and Fumiya Otonashi (shō). They have toured worldwide with Tim Hecker, a world-renowned electronic music artist. They also perform in Hecker’s albums “Konoyo” (2018) and “Anoyo” (2019).
The special unit for the concert was named “CJT+Japonism,” reflecting the artists’ intentions to create music that embodies how Japan is viewed from the world. This concert was actually a rare blessing amid the health crisis, as the performers—usually busy performing around the globe—were confined in Japan due to the outbreak of COVID-19.
The live-streaming featured 9 songs written by Takafumi Kakizaki, composer and drummer of Creative Jazz Trio. The YouTube highlight video includes a full 22-minute performance of “Samsara - Rinnetenshō -”, a song themed on Zen, a school of thoughts on life and death, in which every instrument steals the limelight. Performer interviews are also featured in the video.
The leader of the band, Takafumi Kakizaki, is trained in modern music composition and percussion. He currently creates and performs music across all genres in Tokyo. His activities include performing in Japan tours with WDR Radio Orchestra Cologne Soloclarinetist Andy Miles and Portuguese trumpet player Gileno Santana, playing as an invited guest in France, and organizing master classes in Mexico.
Mixing traditional Japanese music with modern music had been on Takafumi’s mind, triggering him to form “CJT+Japonism” with musicians he had acquainted from past performances.
The group hopes to organize a world tour after the COVID-19 pandemic subsides. Creation of their studio-recorded album is underway. Stay tuned for more news from the group.
WEBSITE: http://cjt.tkdr.net/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005264/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom